La Jolla Institute for Allergy and Immunology

University of California

Sanford Burnham Prebys Medical Discovery Institute

Other

University of Southern California

Nunzio Bottini

Stephanie M Stanford

Anthony B Pinkerton

Robert J Ardecky

Jiwen Zou

Michael P Hedrick

Santhi Reddy Ganji

Thomas D Y Chung

David E Comings

James P MacMurray

Gary S Firestein

Amy M Barrios

Sayantan Mitra

David A McBride

Cristiano Sacchetti

Stephanie Stanford

Nisarg Shah

Santhi R Ganji

Thomas Chung

Described herein are compositions and methods for treating inflammatory arthritic conditions that are effective systemically without causing generalized immunosuppression when administered locally into an inflammatory arthritis-affected joint or a draining lymph node of the arthritis-affected joint of a patient.

Immunoregulatory microparticles for modulating inflammatory arthritides

Methods of treating fibrotic diseases and disorders including Systemic sclerosis (SSc) are provided. Methods include, for example, administering to a subject an effective amount of an antagonist/inhibitor of PTP4A1 protein expression or activity to treat a fibrotic disease or disorder such as SSc, or an associated pathology such as organ or skin fibrosis.

PTP4A1 as a therapeutic target for fibrotic diseases and disorders including systemic sclerosis

Herein are provided, inter, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A). 

Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof

Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A). 

Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (PT-PRA) antagonist.

Modulation of PTPRA to treat arthritis

There are provided, inter alia, methods and compositions to treat autoimmune disease including invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis.

Autoimmune disease treatments

The invention relates in general to tyrosine dephosphorylation. More specifically, the invention relates to methods and compositions for monitoring intracellular tyrosine dephosphorylation at the single cell level. The invention further relates to techniques that can be used as aid in the development of novel therapeutics, and monitor regulation of intracellular tyrosine phosphatase activity at the single cell level.

Method for monitoring intracellular tyrosine phosphatase activity

The ACP1 *A allele provides a means for diagnosing susceptibility of a human subject to hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome, a means for treating, or preventing the onset of, hyperlipidemia and metabolic syndrome, and a means for screening and identifying drugs suitable for use in treating or preventing hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome. Diagnostic kits are also provided.

Growing community of inventors

San Diego, CA, United States of America

Nunzio Bottini